
Less than one year after Adcendo selected its primary drug candidate, the Danish biotech firm has raised more than EUR 51m (USD 61.8m) in a series A financing round.
The investor syndicate is led by Novo Seeds and Ysios Capital but also includes RA Capital Management, HealthCap and Gilde Healthcare.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.